Home » Merck Hepatitis C Drug May “Anchor” Future Worldwide Regimen
Merck Hepatitis C Drug May “Anchor” Future Worldwide Regimen
Merck will make whatever deals are necessary to ensure the company leads the race for future hepatitis C combination therapies, said Roger Pomerantz, the drugmaker’s worldwide head of licensing and acquisitions.
Bloomberg
Bloomberg
Upcoming Events
-
07May
-
14May
-
30May